Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer.
Previous studies have investigated the prognostic significance of B7 homolog 3 (B7-H3) in non-small cell lung cancer (NSCLC), however, the results remain controversial. This study was aimed to determine the correlation between B7-H3 and survival as well as clnicalpathological characteristics in NSCLC using meta-analysis. We searched the electronic databases of PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) for relevant studies up to October 9, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the impact of B7-H3 on overall survival (OS). Combined odds ratios (ORs) and 95%CIs were utilized to evaluate the correlations between B7-H3 and clinicalpathological features. This meta-analysis finally included 7 studies with 864 patients. The results showed that B7-H3 had no significant association with OS (HR=0.88, 95%CI: 0.36-2.13, p=0.776). High B7-H3 expression was a significant indicator of lymph node metastasis (OR=3.92, 95%CI: 2.65-5.81, p<0.001), and advanced TNM stage (OR=3.53, 95%CI: 2.45-5.09, p<0.001). B7-H3 has the potential to serve as a marker of tumor aggressiveness and lymph node metastasis in NSCLC. However, due to several limitations, further large-scale studies are needed to validate our results.
Postgraduate Team, Chinese PLA General Hospital, Beijing 100853, China.|Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Shanshan
S
Wu
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Xiangfei
X
Zhao
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Sudong
S
Wu
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Rui
R
Du
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Qi
Q
Zhu
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Henghu
H
Fang
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Xinhong
X
Zhang
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Chunyang
C
Zhang
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Wei
W
Zheng
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Jihua
J
Yang
Department of Radiation Oncology, Navy General Hospital, Beijing 100048, China.
Huasong
H
Feng
D060887:B7 Antigens / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D016014:Linear Models; D008175:Lung Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D016017:Odds Ratio; D012307:Risk Factors; D016896:Treatment Outcome; D015854:Up-Regulation
D060887:B7 Antigens; D014408:Biomarkers, Tumor; C423237:CD276 protein, human
B7-H3; clinical; lung cancer; meta-analysis; prognosis